AVL 3288

Drug Profile

AVL 3288

Alternative Names: Anvylic-3288; AVL-3288; UCI-4083

Latest Information Update: 11 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Anvyl Pharmaceuticals
  • Developer Anvyl
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cognition disorders

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 New York State Psychiatric Institute and National Institute of Mental Health initiate a phase I trial for Cognition disorders associated with schizophrenia in USA (PO) (NCT02978599)
  • 01 Aug 2016 University of Colorado and National Institute of Mental Health terminates a phase I trial in Cognition disorders associated with schizophrenia (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top